Reuters logo
BRIEF-Entasis Therapeutics highlights positive Phase 1 data for ETX2514
October 9, 2017 / 12:23 PM / 2 months ago

BRIEF-Entasis Therapeutics highlights positive Phase 1 data for ETX2514

Oct 9 (Reuters) - Entasis Therapeutics Inc

* Entasis Therapeutics highlights positive phase 1 data for ETX2514 at IDWeek 2017, announces plans to advance combination with sulbactam (ETX2514SUL) into Phase 2 trials Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below